Clinical Trials Logo

Filter by:
  • Withdrawn  
  • « Prev · Page [37]
NCT ID: NCT00081068 Withdrawn - Lymphoma Clinical Trials

Alemtuzumab in Treating Patients With Waldenstrom's Macroglobulinemia

Start date: January 2004
Phase: Phase 2
Study type: Interventional

RATIONALE: Monoclonal antibodies, such as alemtuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: This phase II trial is studying how well alemtuzumab works in treating patients with Waldenstrom's macroglobulinemia.

NCT ID: NCT00060554 Withdrawn - Clinical trials for Myocardial Infarction

A Safety and Efficacy Trial Evaluating the Use of Fondaparinux in Percutaneous Coronary Intervention (PCI)(63133)(WITHDRAWN)

Start date: April 2003
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to obtain experience in the use of fondaparinux (Arixtra) as compared to heparin when administered to patients who undergo percutaneous coronary intervention (PCI). PCI is a mechanical procedure used to widen the narrowing in a coronary artery in patients with symptomatic coronary artery disease. Fondaparinux and heparin are drugs that inhibit blood clotting.

NCT ID: NCT00003985 Withdrawn - Lung Cancer Clinical Trials

KRN7000 in Treating Patients With Solid Tumors

Start date: September 1998
Phase: Phase 1
Study type: Interventional

RATIONALE: Biological therapies such as KRN7000 use different ways to stimulate the immune system and stop cancer cells from growing. PURPOSE: Phase I trial to study the effectiveness of KRN7000 in treating patients who have solid tumors that have not responded to previous treatment.

NCT ID: NCT00003984 Withdrawn - Clinical trials for Myelodysplastic Syndromes

Monoclonal Antibody Therapy in Treating Patients With Primary Myelodysplastic Syndrome

Start date: February 1999
Phase: Phase 2
Study type: Interventional

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of monoclonal antibody therapy in treating patients who have primary myelodysplastic syndrome.

NCT ID: NCT00003979 Withdrawn - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

CHS 828 in Treating Patients With Solid Tumors

Start date: April 1999
Phase: Phase 1
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of CHS 828 in treating patients who have solid tumors.